Core Viewpoint - Hangzhou Deshi Biotechnology Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, with Huatai International as the sole sponsor, after a previous attempt in June 2025 [1] Group 1: Company Overview - Deshi Biotechnology focuses on developing medical imaging products and services [1] - The company has a diversified product portfolio aimed at enhancing diagnostic efficiency and service quality [1] Group 2: Product Offerings - The product lineup includes six medical imaging software products, featuring the core product AI AutoVision, a commercial product AutoVision, and four candidates in preclinical stages [1] - Additionally, the company offers three commercialized medical devices and four main reagents and consumables [1] - Deshi Biotechnology also provides technology licensing services to meet the needs of various medical institutions, academic research institutions, and regional medical organizations [1]
德适生物再度递表港交所
Zhi Tong Cai Jing·2026-01-06 22:29